89BIO INC. - COMMON STOCK
11.06
21-February-25 15:45:00
15 minutes delayed
Stocks
+0.10
+0.91%
Today's range
10.88 - 11.23
ISIN
N/A
Source
NASDAQ
-
89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH
10 Jun 2021 07:30:00 By Nasdaq GlobeNewswire
-
89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
12 May 2021 15:05:00 By Nasdaq GlobeNewswire
-
89bio to Present at Upcoming Investor Conferences
05 May 2021 07:00:01 By Nasdaq GlobeNewswire
-
89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH
05 Apr 2021 07:00:01 By Nasdaq GlobeNewswire
-
89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
24 Mar 2021 15:05:00 By Nasdaq GlobeNewswire
-
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference
20 Mar 2021 10:00:00 By Nasdaq GlobeNewswire
-
89bio to Present at the Oppenheimer 31st Annual Healthcare Conference
11 Mar 2021 07:00:01 By Nasdaq GlobeNewswire
-
89bio to Participate in the H.C. Wainwright Global Life Sciences Conference
03 Mar 2021 07:00:02 By Nasdaq GlobeNewswire
-
89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference
24 Feb 2021 07:00:01 By Nasdaq GlobeNewswire
-
89bio to Present at the SVB Leerink 10ᵗʰ Annual Global Healthcare Conference
18 Feb 2021 07:00:02 By Nasdaq GlobeNewswire
-
89bio Provides Business Outlook for 2021
05 Jan 2021 07:00:02 By Nasdaq GlobeNewswire
-
89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference
04 Jan 2021 07:00:01 By Nasdaq GlobeNewswire